MYCOLab Ai Logo - gold and army green

Current situation regarding psychedelics and magic mushroom in Korea

Summary

This article reviews the current status of psychedelic mushrooms and their potential medical uses in Korea. Several wild mushroom species containing psilocybin have been identified in Korea and can cause hallucinations and other nervous system effects lasting a few hours. While psychedelics show promise for treating depression and anxiety, Korea currently classifies them as controlled substances, and only approved clinical trials can be conducted with government permission.

Background

Psychedelics have been historically prohibited since 1970 due to harmful effects, but recent clinical research has demonstrated potential medical efficacy for treatment-resistant depression, alcohol dependence, and anxiety in terminal cancer patients. Korea is currently debating the medical use of psychedelics and magic mushrooms, following earlier controversies regarding medical marijuana. This review examines wild mushrooms containing hallucinogenic ingredients found in Korea.

Objective

To establish consensus on the medical use of psychedelic substances by reviewing wild mushrooms containing hallucinogenic ingredients that are native to Korea. The study aims to inform policy decisions regarding potential therapeutic applications of these compounds.

Results

Five wild mushroom species containing psilocybin were identified in Korea: P. argentipes, P. coprophila, P. perdaria, and P. subcarulipes. Psilocybin causes hallucinations with intoxication symptoms lasting 2-4 hours, most resolving within six hours, including nervous symptoms and behavioral changes. Korea has documented acute poisoning cases from mushroom ingestion but lacks records of abuse or dependence from psychedelic mushrooms.

Conclusion

Psilocybin and Psilocin are currently classified as psychotropic drugs by Korean law, with clinical trials possible only through Korean FDA approval. Extensive clinical studies are needed in Korea to determine the therapeutic usefulness of psychedelics and establish evidence-based medical applications.
  • Published in:European Psychiatry,
  • Study Type:Review,
  • Source: 10.1192/j.eurpsy.2024.1695, PMC11862319
Scroll to Top